ERBB2 and breast carcinoma: Generally, loss of HER2, ER, and PR expression refers to as triple-negative breast cancer cells (e.g., MDA-MB-231), while ER and PR positive cells were less malignant as luminal A breast cancer cells (e.g., MCF-7).